GB 235
Alternative Names: GB-235; GB235-019Latest Information Update: 28 Sep 2022
At a glance
- Originator Unknown
- Developer Genor Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Breast-cancer in China (Parenteral)
- 08 Sep 2020 Preclinical trials in Breast cancer is still ongoing in China (Genor Biopharma pipeline, August 2020)
- 26 Aug 2020 Genor Biopharma plans a phase I trial in Breast cancer